版本:
中国

BRIEF-Global Blood Therapeutics says EU has designated GBT440 as orphan medicinal product

Nov 30 Global Blood Therapeutics Inc

* Global Blood Therapeutics says European Commission has designated GBT440 as an orphan medicinal product for treatment of sickle cell disease

* Global Blood Therapeutics says EC acted on a positive recommendation from committee for orphan medicinal products of European medicines agency Source text for Eikon: Further company coverage:

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐